James E. Flynn - 06 Jun 2022 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: * Possible Member of 10% Group, 10%+ Owner
Issuer ticker: MIRM
Reported as of: 06 Jun 2022
Net transaction value: -$962,256
SEC form: 4
Accepted by SEC: 08 Jun 2022, 19:25:31 UTC
Prior SEC filing: 10 May 2022
Next SEC filing: 20 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 08 Jun 2022.

Key facts

This page summarizes James E. Flynn's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
6 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Jun 2022, 19:25.

Change

Previous filing in this sequence was filed on 10 May 2022.
Current net transaction value: -$962,256.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Sale

Transaction value: $332,108
Shares: -13,132
Change %: -0.76%
Price: $25.29
Shares after: 1,711,324
Date: 06 Jun 2022
Ownership: Through Deerfield Private Design Fund IV, L.P.
Footnotes: F1, F2

MIRM transaction

Common Stock

Sale

Transaction value: $300,142
Shares: -11,868
Change %: -0.76%
Price: $25.29
Shares after: 1,546,588
Date: 06 Jun 2022
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F1, F2

MIRM transaction

Common Stock

Sale

Transaction value: $4,289
Shares: -171
Change %: -0.01%
Price: $25.08
Shares after: 1,711,153
Date: 06 Jun 2022
Ownership: Through Deerfield Private Design Fund IV, L.P.
Footnotes: F1, F2

MIRM transaction

Common Stock

Sale

Transaction value: $3,887
Shares: -155
Change %: -0.01%
Price: $25.08
Shares after: 1,546,433
Date: 06 Jun 2022
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F1, F2

MIRM transaction

Common Stock

Sale

Transaction value: $169,063
Shares: -6,909
Change %: -0.4%
Price: $24.47
Shares after: 1,704,244
Date: 06 Jun 2022
Ownership: Through Deerfield Private Design Fund IV, L.P.
Footnotes: F1, F2

MIRM transaction

Common Stock

Sale

Transaction value: $152,766
Shares: -6,243
Change %: -0.4%
Price: $24.47
Shares after: 1,540,190
Date: 06 Jun 2022
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James E. Flynn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund IV, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

Footnote F2

In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.